Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRA-TBE
2023-509575-16-00Phase 4Authorised
- Sponsor
- Region Västra Götaland
- Start
- May 2024
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of FSME-IMMUN and Tick-borne encephalitis vaccine in tick-borne encephalitis (TBE) (3 arms), sponsored by Region Västra Götaland. Planned start May 2024; status: authorised.
02
Drugs
FSME-IMMUNTick-borne encephalitis vaccine
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on 2023-509575-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509575-16-00.